Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Ribociclib improves PFS for postmenopausal women with hormone receptor-positive breast cancer

ESMO 2016

7 - 11 Oct 2016

Published: 8 Oct 2016

Views: 3582

Rating:

Save

Dr Gabriel Hortobagyi - MD Anderson, Houston, USA

Dr Hortobagyi talks to ecancertv at ESMO 2016 about how the addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improved progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer.

Read the news story or watch the press conference video for more.

Supported by a grant from Pfizer Inc.

Related Videos

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer

Dr James Martin - Cleveland Clinic, Cleveland, USA

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )

Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients

Dr Prashant Mehta - Amrita Hospital, Karala, India

Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients ( Dr Prashant Mehta - Amrita Hospital, Karala, India )

Advancements in head and neck cancer treatment in India

Dr Amol Akhade - Tata Memorial Hospital, Mumbai, India

Advancements in head and neck cancer treatment in India ( Dr Amol Akhade - Tata Memorial Hospital, Mumbai, India )

Advancements in paediatric Acute lymphoblastic leukemia management

Dr Ruchi Aujla - Balco Medical Center, Raipur, India

Advancements in paediatric Acute lymphoblastic leukemia management ( Dr Ruchi Aujla - Balco Medical Center, Raipur, India )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

Choosing 1st line TKI Wisely in patients with CML

Dr Prashant Mehta - Amrita Hospirtal, Karala, India

Choosing 1st line TKI Wisely in patients with CML ( Dr Prashant Mehta - Amrita Hospirtal, Karala, India )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Updates on triple-negative breast cancer and immunotherapy

Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA

Updates on triple-negative breast cancer and immunotherapy ( Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA )

More from ecancer